– Dr. Laura Bessen brings more than two decades of medical affairs and clinical development experience to support successful product launches –
– Dr. Donna Grogan joins as an accomplished drug development and regulatory strategy executive with over 25 years of experience developing novel therapies –
– Appointments Highlight C4T’s Continued Commitment to Evolving Board Composition –
WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (CCCC), a clinical-stage biopharmaceutical company dedicated to advancing the science of targeted protein degradation to develop next-generation small molecule drugs and transform the way disease is treated, today announced the appointments of Laura Bessen, MD and Donna Grogan, MD to its Board of Directors.
“We are thrilled to announce Laura and Donna as the new directors of C4T after an extensive search that included a talented and diverse group of experienced clinical development leaders to help companies bring innovative therapies to patients,” said Bruce. Downey, president of C4 Therapeutics. “On behalf of the Board, I look forward to working closely with Laura and Donna as C4T continues to evolve in our quest to harness the potential of targeted protein degradation science to create a new generation of drugs and changing the way diseases are treated. .”
“I look forward to using my extensive experience in medical affairs and clinical development to help C4T advance multiple oncology programs for the benefit of patients,” said Laura Bessen, MD “C4T is at a transformative stage, with two programs in the clinic and additional programs in preparation to move into clinical trials, I am excited to help C4T take advantage of the opportunities ahead.
Commenting on joining the C4T Board of Directors, Donna Grogan, MD, said, “This is an exciting time to join C4T and partner with the company to navigate drug development and regulatory milestones to make advance an innovative portfolio of small molecule drugs. I look forward to working with my colleagues at C4T to help the company apply its industry-leading targeted protein degradation science to transform the way patients are treated.
About Laura Bessen, MD
Laura Bessen, MD, is currently Managing Partner at Maxsam Advisors LLC, where she provides strategic clinical and medical affairs advice to clients in the biotechnology and pharmaceutical industries. Previously, she held positions of increasing responsibility during a 15-year career at Bristol Myers Squibb (BMS), most recently as Vice President, Head of US Medical. During her tenure at BMS, she participated in the launch of 11 new products, including Opdivo®Yervoy®elotuzomab and Eliquis® and co-led BMS’s partnership with Gilead to develop Atripla®. Dr. Bessen also co-led the development of the BMS product commercialization model, life cycle management and launch investment principles. Earlier in his career, Dr. Bessen held positions in medical affairs at DuPont Pharmaceuticals. She currently serves on the board of directors of Artiva Biotherapeutics, an oncology company that develops and advances ready-to-use allogeneic natural killer cell therapies for patients with hematologic cancers or solid tumors. Dr. Bessen received his medical degree from New York University School of Medicine and his BS in Biochemistry from the State University of New York at Binghamton.
About Donna Grogan, MD
Donna Grogan, MD, is currently Principal of Grogan Consulting LLC, where she assists clients with drug development, regulatory strategy, trial design and data interpretation. Between September 2013 and June 2019, Dr. Grogan served as Chief Medical Officer of Clementia Pharmaceuticals, which was acquired by Ipsen in April 2019. She previously served as Chief Medical Officer for several HealthCare Ventures portfolio companies , including Anexon, Apofore and DecImmune. Between February 2007 and August 2011, Dr. Grogan served as Chief Medical Officer, Senior Vice President of Clinical Development at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. Earlier in her career, she held positions of increasing responsibility at Sepracor, Inc. where she was involved in several high-level product approvals, including Lunesta®Xopenex HFA®and Brovana™. Dr. Grogan previously served as a member of the board of directors, including a member of the compensation committee and the scientific committee, of Momenta Pharmaceuticals until its acquisition by J&J in October 2020. She holds an MD from the College in Medicine from the University of Illinois and a BA from the College. of the Holy Cross.
About C4 Therapeutics
C4 Therapeutics (C4T) (CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of science of targeted protein degradation to create a new generation of medicines that transform patients’ lives. C4T relies on its TORPEDO® platform to efficiently design and optimize small molecule drugs that harness the body’s natural protein recycling system to rapidly degrade pathogenic proteins, offering the potential to overcome drug resistance, non-drug drug targets and d improve patient outcomes. C4T is advancing several targeted oncology programs into the clinic and expanding its research platform to deliver the next wave of drugs for hard-to-treat diseases. For more information, please visit www.c4therapeutics.com.
This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, but are not limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential effectiveness of our therapeutic approaches; the predictive capacity of our TORPEDO® development platform for new selective and bioavailable degraders orally; the potential timing, design and progress of our preclinical studies and clinical trials, including the potential timing of regulatory approval related to clinical trials and other clinical development activities; our ability and potential to successfully manufacture and deliver our product candidates for clinical trials; our ability to replicate the results obtained in our preclinical studies or clinical trials in any future study or trial; and regulatory developments in the United States and in foreign countries. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. – look at the statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, progress and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that one or more of our product candidates will cost more to develop or will not be successfully developed and commercialized; and the risk that the results of preclinical studies and/or clinical trials may or may not be predictive of results in future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, each of which could cause our actual results to differ materially from those contained in the forward-looking statements, see the section entitled “Risk Factors”. in the most recent publication of C4 Therapeutics. Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of publication, and C4 Therapeutics undertakes no obligation to update this information except as required by law.
SVP, Communications and Investor Relations
Director, Corporate Communications and Patient Advocacy
Photos accompanying this announcement are available at: